Guanylate cyclase-C/cGMP: An emerging pathway in the regulation of visceral pain

Frontiers in Molecular Neuroscience

Volumn 7, Issue 1 APR, 2014, Pages

  Hannig, Gerhard ^a   Tchernychev, Boris ^a   Kurtz, Caroline B ^a   Bryant, Alexander P ^a   Currie, Mark G ^a   Silos Santiago, Inmaculada ^a  

^a IRONWOOD PHARMACEUTICALS INC   (United States)

Author keywords

Abdominal pain; Colonic nociceptor; Cyclic guanosine monophosphate; Guanylate cyclase C; Irritable bowel syndrome with constipation; Linaclotide; Uroguanylin; Visceral analgesia

Indexed keywords

GUANYLATE CYCLASE; GUANYLIN; LINACLOTIDE; PLACEBO; UROGUANYLIN;

ABDOMINAL PAIN; ALLODYNIA; ANALGESIC ACTIVITY; CONSTIPATION; HUMAN; INFLAMMATION; IRRITABLE COLON; MECHANICAL STIMULATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; VISCERAL PAIN;

EID: 84898908300     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00031     Document Type: Review

References (43)

1. Bouin, M., Plourde, V., Boivin, M., Riberdy, M., Lupien, F., Laganiere, M., et al. (2002). Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122, 1771-1777. doi: 10. 1053/gast. 2002. 33601.
2. Blackshaw, L. A., and Brierley, S. M. (2013). Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation. Expert Rev. Gastroenterol. Hepatol. 7(Suppl. 1), 15-19. doi: 10. 1586/17474124. 2013. 820045.
3. Bryant, A. P., Busby, R. W., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., et al. (2010). Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 86, 760-765. doi: 10. 1016/j. lfs. 2010. 03. 015.
4. Busby, R. W., Bryant, A. P., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., et al. (2010). Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649, 328-335. doi: 10. 1016/j. ejphar. 2010. 09. 019.
5. Busby, R. W., Kessler, M. M., Bartolini, W. P., Bryant, A. P., Hannig, G., Higgins, C. S., et al. (2013). Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J. Pharmacol. Exp. Ther. 344, 196-206. doi: 10. 1124/jpet. 112. 199430.
6. Carrithers, S. L., Barber, M. T., Biswas, S., Parkinson, S. J., Park, P. K., Goldstein, S. D., et al. (1996). Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl. Acad. Sci. U. S. A. 93, 14827-14832. doi: 10. 1073/pnas. 93. 25. 14827.
7. Castro, J., Harrington, A. M., Hughes, P. A., Martin, C. M., Ge, P., Shea, C. M., et al. (2013). Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic GMP. Gastroenterology 145, 1334-1346. doi: 10. 1053/j. gastro. 2013. 08. 017.
8. Cervetto, C., Maura, G., and Marcoli, M. (2010). Inhibition of presynaptic release-facilitatory kainate autoreceptors by extracellular cyclic GMP. J. Pharmacol. Exp. Ther. 332, 210-219. doi: 10. 1124/jpet. 109. 154955.
9. Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., et al. (2012). Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am. J. Gastroenterol. 107, 1702-1712. doi: 10. 1038/ajg. 2012. 254.
10. Currie, M. G., Fok, K. F., Kato, J., Moore, R. J., Hamra, F. K., Duffin, K. L., et al. (1992). Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc. Natl. Acad. Sci. U. S. A. 89, 947-951. doi: 10. 1073/pnas. 89. 3. 947.
11. Drossman, D. A. (2006). The functional gastrointestinal disorders and the Rome III process. Gastroenterology130, 1377-1390. doi: 10. 1053/j. gastro. 2006. 03. 008.
12. Eutamene, H., Bradesi, S., Larauche, M., Theodorou, V., Beaufrand, C., Ohning, G., et al. (2010). Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol. Motil. 22, 312-e84. doi: 10. 1111/j. 1365-2982. 2009. 01385. x.
13. Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., and Poole, R. M. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149-158. doi: 10. 1016/S0304-3959(01)00349-9.
14. Feng, B., and Gebhart, G. F. (2011). Characterization of silent afferents in the pelvic and splanchnic innervations of the mouse colorectum. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G170-G180. doi: 10. 1152/ajpgi. 00406. 2010.
15. Feng, B., Kiyatkin, M. E., La, J.-H., Ge, P., Solinga, R., Silos-Santiago, I., et al. (2013). Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents. J. Neurosci. 33, 9831-9839. doi: 10. 1523/JNEUROSCI. 5114-12. 2013.
16. Food and Drug Administration. (2010). Guidance for industry. Irritable bowel syndrome-clinical evaluation of products for treatment. Available at: http://www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default. htm (accessed August 1, 2012).
17. Forte, L. R. (1999). Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul. Pept. 81, 25-39. doi: 10. 1016/S0167-0115(99)00033-6.
18. Hughes, P. A., Brierley, S. M., Martin, C. M., Brookes, S. J., Linden, D. R., and Blackshaw, L. A. (2009). Post-inflammatory colonic afferent sensitization: different subtypes, different pathways and different time courses. Gut58, 1333-1341. doi: 10. 1136/gut. 2008. 170811.
19. Johnston, J. M., Shiff, S. J., and Quigley, E. M. M. (2013). A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr. Med. Res. Opin. 29, 149-160. doi: 10. 1185/03007995. 2012. 754743.
20. Kita, T., Smith, C. E., Fok, K. F., Duffin, K. L., Moore, W. M., Karabatsos, P. J., et al. (1994). Characterization of human uroguanylin: a member of the guanylin peptide family. Am. J. Physiol. 266, F342-F348.
21. Linden, D. J., Dawson, T. M., and Dawson, V. L. (1995). An evaluation of the nitric oxide/cGMP/cGMP-dependent protein kinase cascade in the induction of cerebellar long-term depression in culture. J. Neurosci. 15, 5098-5105.
22. Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., et al. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-413.
23. Mann, E. A., Jump, M. L., Wu, J., Yee, E., and Giannella, R. A. (1997). Mice lacking the guanylate cyclase C receptor are resistant to STa-induced intestinal secretion. Biochem. Biophys. Res. Commun. 239, 463-466. doi: 10. 1006/bbrc. 1997. 7487.
24. Marx, U. C., Klodt, J., Meyer, M., Gerlach, H., Roesch, P., Forssmann, W. G., et al. (1998). One peptide, two topologies: structure and interconversion dynamics of human uroguanylin isomers. J. Pept. Res. 52, 229-240. doi: 10. 1111/j. 1399-3011. 1998. tb01480. x.
25. Mertz, H., Naliboff, B., Munakata, J., Niazi, N., and Mayer, E. A. (1995). Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109, 40-52. doi: 10. 1016/0016-5085(95)90267-8.
26. Perkins, A., Goy, M. F., and Li, Z. (1997). Uroguanylin is expressed by enterochromaffin cells in the rat gastrointestinal tract. Gastroenterology 113, 1007-1014. doi: 10. 1016/S0016-5085(97)70198-7.
27. Pfeifer, A., Aszodi, A., Seidler, U., Ruth, P., Hofmann, F., and Faessler, R. (1996). Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 274, 2082-2085. doi: 10. 1126/science. 274. 5295. 2082.
28. Poupoloupou, C., and Nowak, L. M. (1998). Extracellular 3′, 5′ cyclic guanosine monophosphate inhibits kainate-activated responses in cultured mouse cerebellar neurons. J. Pharmacol. Exp. Ther. 286, 99-109.
29. Qian, X., Prabhakar, S., Nandi, A., Visweswariah, S. S., and Goy, M. F. (2000). Expression of GC-C, a receptor-guanylate cyclase, and its endogenous ligands uroguanylin and guanylin along the rostrocaudal axis of the intestine. Endocrinology 141, 3210-3224.
30. Rao, S., Lembo, A. J., Shiff, S. J., Lavins, B. J., Currie, M. G., Jia, X. D., et al. (2012). A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am. J. Gastroenterol. 107, 1714-1724. doi: 10. 1038/ajg. 2012. 255.
31. Ritter, C. A., Jedlitschky, G., Meyer zu Schwabedissen, H., Grube, M., Köck, K., and Kroemer, H. K. (2005). Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37, 253-278. doi: 10. 1081/DMR-200047984.
32. Sager, G. (2004). Cyclic GMP transporters. Neurochem. Int. 45, 865-873. doi: 10. 1016/j. neuint. 2004. 03. 017.
33. Schlossman, J., Feil, R., and Hofmann, F. (2005). Insights into cGMP signaling derived from cGMP kinase knockout mice. Front. Biosci. 10: 1279-1289. doi: 10. 2741/1618.
34. Schulz, S., Green, C. K., Yuen, P. S., and Garbers, D. L. (1990). Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 63, 941-948. doi: 10. 1016/0092-8674(90)90497-3.
35. Schulz, S., Lopez, M. J., Kuhn, M., and Garbers, D. L. (1997). Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J. Clin. Invest. 100, 1590-1595. doi: 10. 1172/JCI119683.
36. Silos-Santiago, I., Hannig, G., Eutamene, H., Ustinova, E. E., Bernier, S. G., Ge, P., et al. (2013). Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation. Pain154, 1820-1830. doi: 10. 1016/j. pain. 2013. 05. 044.
37. Sindic, A., and Schlatter, E. (2006). Cellular effects of guanylin and uroguanylin. J. Am. Soc. Nephrol. 17, 607-616. doi: 10. 1681/ASN. 2005080818.
38. Skelton, N. J., Garcia, K. C., Goeddel, D. V., Quan, C., and Burnier, J. P. (1994). Determination of the solution structure of the peptide hormone guanylin: observation of a novel form of topological stereoisomerism. Biochemistry 33, 13581-13592. doi: 10. 1021/bi00250a010.
39. Spiegel, B., Bolus, R., Harris, L. A., Lucak, S., Naliboff, B., Esrailian, E., et al. (2009). Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment. Pharmacol. Ther. 30, 1159-1170. doi: 10. 1111/j. 1365-2036. 2009. 04144. x.
40. Tack, J., Talley, N. J., Camilleri, M., Holtmann, G., Hu, P., Malagelada, J. R., et al. (2006). Functional gastroduodenal disorders. Gastroenterology 130, 1466-1479. doi: 10. 1053/j. gastro. 2005. 11. 059.
41. Vaandrager, A. B. (2002). Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol. Cell. Biochem. 230, 73-83. doi: 10. 1023/A: 1014231722696.
42. Videlock, E. J., and Chang, L. (2007). Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol. Clin. North Am. 36, 665-685. doi: 10. 1016/j. gtc. 2007. 07. 002.
43. Zimmermann, C., Gutmann, H., Hruz, P., Gutzwiller, J. P., Beglinger, C., and Drewe, J. (2005). Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 and 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33, 219-224. doi: 10. 1124/dmd. 104. 001354.